FDA Declines Review of Moderna’s Flu Vaccine Application Citing Study Design Issues

Cambridge, Wednesday, 11 February 2026.
The FDA rejected Moderna’s application over comparator selection—a decision management calls inconsistent with prior feedback—triggering a 9% stock drop despite unchanged 2026 financial guidance.